Literature DB >> 35404674

Challenges and Gaps in Clinical Trial Genomic Data Management.

Sarah Asad1, Kathryn Kananen1, Kurt R Mueller1, W Fraser Symmans2, Yujia Wen3, Charles M Perou4, James S Blachly1, James Chen1, Benjamin G Vincent4, Daniel G Stover1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35404674      PMCID： PMC9012601          DOI： 10.1200/CCI.21.00193

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN： 2473-4276


× No keyword cloud information.
  20 in total

Review 1.  Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.

Authors:  M L Telli; D G Stover; S Loi; S Aparicio; L A Carey; S M Domchek; L Newman; G W Sledge; E P Winer
Journal:  Breast Cancer Res Treat       Date:  2018-05-07       Impact factor: 4.872

2.  Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Authors:  Hope S Rugo; Olufunmilayo I Olopade; Angela DeMichele; Christina Yau; Laura J van 't Veer; Meredith B Buxton; Michael Hogarth; Nola M Hylton; Melissa Paoloni; Jane Perlmutter; W Fraser Symmans; Douglas Yee; A Jo Chien; Anne M Wallace; Henry G Kaplan; Judy C Boughey; Tufia C Haddad; Kathy S Albain; Minetta C Liu; Claudine Isaacs; Qamar J Khan; Julie E Lang; Rebecca K Viscusi; Lajos Pusztai; Stacy L Moulder; Stephen Y Chui; Kathleen A Kemmer; Anthony D Elias; Kirsten K Edmiston; David M Euhus; Barbara B Haley; Rita Nanda; Donald W Northfelt; Debasish Tripathy; William C Wood; Cheryl Ewing; Richard Schwab; Julia Lyandres; Sarah E Davis; Gillian L Hirst; Ashish Sanil; Donald A Berry; Laura J Esserman
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

3.  Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

Authors:  Sibylle Loibl; Joyce O'Shaughnessy; Michael Untch; William M Sikov; Hope S Rugo; Mark D McKee; Jens Huober; Mehra Golshan; Gunter von Minckwitz; David Maag; Danielle Sullivan; Norman Wolmark; Kristi McIntyre; Jose J Ponce Lorenzo; Otto Metzger Filho; Priya Rastogi; W Fraser Symmans; Xuan Liu; Charles E Geyer
Journal:  Lancet Oncol       Date:  2018-02-28       Impact factor: 41.316

4.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers.

Authors:  Sohrab P Shah; Andrew Roth; Rodrigo Goya; Arusha Oloumi; Gavin Ha; Yongjun Zhao; Gulisa Turashvili; Jiarui Ding; Kane Tse; Gholamreza Haffari; Ali Bashashati; Leah M Prentice; Jaswinder Khattra; Angela Burleigh; Damian Yap; Virginie Bernard; Andrew McPherson; Karey Shumansky; Anamaria Crisan; Ryan Giuliany; Alireza Heravi-Moussavi; Jamie Rosner; Daniel Lai; Inanc Birol; Richard Varhol; Angela Tam; Noreen Dhalla; Thomas Zeng; Kevin Ma; Simon K Chan; Malachi Griffith; Annie Moradian; S-W Grace Cheng; Gregg B Morin; Peter Watson; Karen Gelmon; Stephen Chia; Suet-Feung Chin; Christina Curtis; Oscar M Rueda; Paul D Pharoah; Sambasivarao Damaraju; John Mackey; Kelly Hoon; Timothy Harkins; Vasisht Tadigotla; Mahvash Sigaroudinia; Philippe Gascard; Thea Tlsty; Joseph F Costello; Irmtraud M Meyer; Connie J Eaves; Wyeth W Wasserman; Steven Jones; David Huntsman; Martin Hirst; Carlos Caldas; Marco A Marra; Samuel Aparicio
Journal:  Nature       Date:  2012-04-04       Impact factor: 49.962

5.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

Authors:  William M Sikov; Donald A Berry; Charles M Perou; Baljit Singh; Constance T Cirrincione; Sara M Tolaney; Charles S Kuzma; Timothy J Pluard; George Somlo; Elisa R Port; Mehra Golshan; Jennifer R Bellon; Deborah Collyar; Olwen M Hahn; Lisa A Carey; Clifford A Hudis; Eric P Winer
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544

6.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

7.  The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.

Authors:  Daniel G Stover; Jonathan L Coloff; William T Barry; Joan S Brugge; Eric P Winer; Laura M Selfors
Journal:  Clin Cancer Res       Date:  2016-06-21       Impact factor: 12.531

8.  Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.

Authors:  Otto Metzger Filho; Daniel G Stover; Sarah Asad; Peter J Ansell; Mark Watson; Sibylle Loibl; Charles E Geyer; Junu Bae; Katharine Collier; Mathew Cherian; Joyce O'Shaughnessy; Michael Untch; Hope S Rugo; Jens B Huober; Mehra Golshan; William M Sikov; Gunter von Minckwitz; Priya Rastogi; David Maag; Norman Wolmark; Carsten Denkert; W Fraser Symmans
Journal:  JAMA Oncol       Date:  2021-04-01       Impact factor: 31.777

9.  Predicting response and survival in chemotherapy-treated triple-negative breast cancer.

Authors:  A Prat; A Lluch; J Albanell; W T Barry; C Fan; J I Chacón; J S Parker; L Calvo; A Plazaola; A Arcusa; M A Seguí-Palmer; O Burgues; N Ribelles; A Rodriguez-Lescure; A Guerrero; M Ruiz-Borrego; B Munarriz; J A López; B Adamo; M C U Cheang; Y Li; Z Hu; M L Gulley; M J Vidal; B N Pitcher; M C Liu; M L Citron; M J Ellis; E Mardis; T Vickery; C A Hudis; E P Winer; L A Carey; R Caballero; E Carrasco; M Martín; C M Perou; E Alba
Journal:  Br J Cancer       Date:  2014-08-07       Impact factor: 7.640

10.  Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

Authors:  Brian D Lehmann; Bojana Jovanović; Xi Chen; Monica V Estrada; Kimberly N Johnson; Yu Shyr; Harold L Moses; Melinda E Sanders; Jennifer A Pietenpol
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.